“Selecting the Optimal Treatment Line for CDK4/6 Inhibitors in Hormone Receptor-Positive, HER2-Negative Breast Cancer” (2026) Voprosy onkologii, 72(3), p. OF-2455. doi:10.37469/0507-3758-2026-72-3-OF-2455.